Covered recipient · General Payments record
HOWARD L CHAMBERLAIN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,759.34
- Reported across 234 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $561.70 | 32 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $222.30 | 15 |
| PFIZER INC. | $47.61 | 3 |
| Sumitomo Pharma America, Inc. | $40.92 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $38.05 | 1 |
| Amgen Inc. | $31.31 | 1 |
| Janssen Pharmaceuticals, Inc | $23.36 | 1 |
| INOGEN, INC. | $22.42 | 1 |
| Abbott Laboratories | $22.36 | 1 |
| Neurocrine BioSciences, Inc. | $19.28 | 1 |
| Lilly USA, LLC | $17.70 | 1 |
| Medtronic, Inc. | $16.09 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.01 | 1 |
| Merck Sharp & Dohme Corporation | $15.91 | 1 |
| Organon LLC | $14.51 | 1 |
| Antares Pharma, Inc. | $13.87 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (32)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.36 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124979026 | CMS |
| ABBVIE INC. | $15.90 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436206 | CMS |
| ABBVIE INC. | $21.60 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436208 | CMS |
| ABBVIE INC. | $8.82 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436210 | CMS |
| ABBVIE INC. | $20.19 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436212 | CMS |
| ABBVIE INC. | $16.10 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436214 | CMS |
| ABBVIE INC. | $33.75 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436216 | CMS |
| ABBVIE INC. | $2.66 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436218 | CMS |
| ABBVIE INC. | $2.48 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436220 | CMS |
| ABBVIE INC. | $14.70 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436222 | CMS |
| ABBVIE INC. | $9.27 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436224 | CMS |
| ABBVIE INC. | $16.51 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436226 | CMS |
| ABBVIE INC. | $25.89 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436228 | CMS |
| ABBVIE INC. | $1.20 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436230 | CMS |
| ABBVIE INC. | $15.61 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436232 | CMS |
| ABBVIE INC. | $17.62 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103436234 | CMS |
| Amgen Inc. | $31.31 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111545203 | CMS |
| Antares Pharma, Inc. | $13.87 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146452566 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.01 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117958396 | CMS |
| Boston Scientific Corporation | $38.05 | 10/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092666129 | CMS |
| INOGEN, INC. | $22.42 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144987518 | CMS |
| Janssen Pharmaceuticals, Inc | $23.36 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078222167 | CMS |
| Lilly USA, LLC | $17.70 | 07/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135004183 | CMS |
| Medtronic, Inc. | $16.09 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117154557 | CMS |
| Merck Sharp & Dohme LLC | $15.91 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141975186 | CMS |
| Neurocrine Biosciences, Inc. | $19.28 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150861359 | CMS |
| Organon Llc | $14.51 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136258429 | CMS |
| PFIZER INC. | $15.41 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131031510 | CMS |
| PFIZER INC. | $15.92 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131767770 | CMS |
| PFIZER INC. | $16.28 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131117894 | CMS |
| Sumitomo Pharma America, Inc. | $23.69 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148836397 | CMS |
| Sumitomo Pharma America, Inc. | $17.23 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148836399 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.